Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-09. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
=== 1990s: Early development of AI and open-source software === The concept of AI dates back to the mid-20th century, when computer scientists like Alan Turing and John McCarthy laid the groundwork for modern AI theories and algorithms. An early form of AI, the natural language processing "doctor" ELIZA, was re-implemented and shared in 1977 by Jeff Shrager as a BASIC program, and soon translated to many other languages. Early AI research focused on developing symbolic reasoning systems and rule-based expert systems. During this period, the idea of open-source software was beginning to take shape, with pioneers like Richard Stallman advocating for free software as a means to promote collaboration and innovation in programming. The Free Software Foundation, founded in 1985 by Stallman, was one of the first major organizations to promote the idea of software that could be freely used, modified, and distributed. The ideas from this movement eventually influenced the development of open-source AI, as more developers began to see the potential benefits of open collaboration in software creation, including AI models and algorithms. In the 1990s, open-source software began to gain more traction, the rise of machine learning and statistical methods also led to the development of more practical AI tools. In 1993, the CMU Artificial Intelligence Repository was initiated, with a variety of openly shared software.
==== Green ==== Feces can be green due to having large amounts of unprocessed bile in the digestive tract and strong-smelling diarrhea. This can occasionally be the result from eating liquorice candy, as it is typically made with anise oil rather than liquorice herb and is predominantly sugar. Excessive sugar consumption or a sensitivity to anise oil may cause loose, green stools. It can also result from consuming excessive amounts of blue or green dye.
This reaction is exploited in native chemical ligation, a protocol for peptide synthesis. In a related reaction, thioesters can be converted into esters. Thioacetate esters can also be cleaved with methanethiol in the presence of stoichiometric base, as illustrated in the preparation of pent-4-yne-1-thiol:
The catalytic domain of MMP-3 can be inhibited by tissue inhibitors of metalloproteinases (TIMPs). The n-terminal fragment of the TIMP binds in the active site cleft much like the peptide substrate would bind. The Cys1 residue of the TIMP chelates to the catalytic zinc and forms hydrogen bonds with one of the carboxylate oxygens of the catalytic glutamate residue (Glu202, see mechanism below). These interactions force the zinc-bound water molecule that is essential to the enzyme's function to leave the enzyme. The loss of the water molecule and the blocking of the active site by TIMP disable the enzyme. The hemopexin-like domain of MMPs is highly conserved and shows sequence similarity to the plasma protein, hemopexin. The hemopexin-like domain has been shown to play a functional role in substrate binding and/or in interactions with the tissue inhibitors of metalloproteinases (TIMPs), a family of specific MMP protein inhibitors.
Sources: en.wikipedia.org
Vitam-R is a savory yeast extract spread made in Hameln, Germany, by the company Vitam Hefe-Produkt GmbH. It was first developed by Rückforth AG in Stettin (today's Szczecin, Poland) in 1925, following the discovery by Justus von Liebig that yeast could be concentrated. It is sometimes described as having a smoother flavour than similar products such as Marmite, Vegemite, or Cenovis. Unlike those brands, Vitam-R is not an iconic part of its home country's cuisine, but it, too, is described as having a love-it-or-hate-it flavour. It is both vegan and by extension, vegetarian, and is sold primarily in Reformhaus health-food stores.
BV(test) = percentage BV of the test diet for that individual BV(egg) = percentage BV of the reference (egg) diet for that individual This is not restricted to values of less than 100. The percentage BV of egg protein is only 93.7% which allows other proteins with true percentage BV between 93.7% and 100% to take a relative BV of over 100. For example, whey protein takes a relative BV of 104, while its percentage BV is under 100%. The principal advantage of measuring BV relative to another protein diet is accuracy; it helps account for some of the metabolic variability between individuals. In a simplistic sense the egg diet is testing the maximum efficiency the individual can take up protein, the BV is then provided as a percentage taking this as the maximum.
Askari had shaken the South African government's confidence in its ability to retain the military advantage indefinitely in Angola. Heavier and more sophisticated weapons were being used, the rate of casualties had increased, and the air superiority that had accounted for many of the SADF's previous successes was diminishing. Nor was Botha and his cabinet certain of continued political and diplomatic support from the US, which had chosen to abstain rather than exercise its veto with regard to UN Security Council Resolution 546. The Reagan administration perceived that both Angola and South Africa had grown weary of the war and were more susceptible to pressure for a ceasefire and mutual disengagement. American diplomats offered to mediate peace talks accordingly, and on 13 February South African and Angolan officials met for the first time in Lusaka. Three days later, South Africa announced that it would withdraw its expeditionary forces from Cunene Province by the end of March, provided the Angolans agreed to prevent PLAN from taking advantage of the situation to infiltrate South West Africa. The Angolan government pledged to restrain PLAN and MK, and to prohibit any movement of Cuban troops southward towards the border. These respective commitments were formalised as the Lusaka Accords. FAPLA and the SADF agreed to set up a Joint Monitoring Commission (JMC) to police the disengagement. Under the JMC, joint South African and Angolan patrols were carried out along six hundred kilometres of the border.
Sources: en.wikipedia.org
Vitamin D deficiency was found to be related to neurological manifestations and the presence of lymphoma among patients. Vitamin A levels were inversely associated with extraglandular manifestations of the disease. Saliva is a potential diagnostic tool for Sjögren's disease because the salivary component is changed after the onset of the disease. With the new miniaturization technology, called lab on a chip, the diagnosis can be more convenient. Concerning therapeutics, multiple monoclonal antibodies were under investigation in 2007. The most promising seemed to be the anti-CD20 rituximab and the anti-CD22 epratuzumab, while the anti-TNF-α and IFN-α seemed less effective. In 2014, the Sjögren's Foundation (previously the Sjögren's Syndrome Foundation) announced a five-year goal to halve the disease's average time to diagnosis. As of 2026, several investigational therapies were in late-stage clinical development for Sjögren's disease. In January 2026, the FDA granted ianalumab Breakthrough Therapy designation for Sjögren's disease. Other agents in phase III development include telitacicept and dazodalibep.
== Alveolodental ligament == The main principal fiber group is the alveolodental ligament, which consists of five fiber subgroups: alveolar crest, horizontal, oblique, apical, and interradicular on multirooted teeth. Principal fibers other than the alveolodental ligament are the transseptal fibers. All these fibers help the tooth withstand the naturally substantial compressive forces that occur during chewing and remain embedded in the bone. The ends of the principal fibers that are within either cementum or alveolar bone proper are considered Sharpey fibers.
== Selected works == Approximately complete analyses of thirty "normal" urines (1905) Chemical problems in hospital practice (1908) Nitrogen retention in the blood in experimental acute nephritis in the cat (1912) Preservatives and other chemicals in foods: Their use and abuse (1914) On the determination of creatinine and creatine in urine (1914) Recent biochemical investigations on blood and urine;: Their bearing on clinical and experimental medicine (1917) A System of Blood Analysis by Folin and Wu (1919) Laboratory Manual of Biological Chemistry with Supplement (1925)
=== Diabetes === There is limited evidence for the effectiveness of low-carbohydrate diets for people with type 1 diabetes. For certain individuals, it may be feasible to follow a low-carbohydrate regime combined with carefully managed insulin dosing. This can be hard to maintain and there are concerns about potential adverse health effects caused by the diet. In general, people with type 1 diabetes are advised to follow an individualized eating plan. The proportion of carbohydrate in a diet is not linked to the risk of type 2 diabetes, although there is some evidence that diets containing certain high-carbohydrate items – such as sugar-sweetened drinks or white rice – are associated with an increased risk. Some evidence indicates that consuming fewer carbohydrate foods may reduce biomarkers of type 2 diabetes. A 2019 consensus report on nutrition therapy for adults with diabetes and prediabetes the American Diabetes Association (ADA) states "Reducing overall carbohydrate intake for individuals with diabetes has demonstrated the most evidence for improving glycemia (blood sugar) and may be applied in a variety of eating patterns that meet individual needs and preferences." However, another source states that there is no good evidence that low-carbohydrate diets are better than a conventional healthy diet in which carbohydrates typically account for more than 40% of calories consumed. Low-carbohydrate dieting has no effect on the kidney function of people who have type 2 diabetes.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.